UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 422,290 Shares of Boston Scientific Corporation $BSX

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in shares of Boston Scientific Corporation (NYSE:BSX) by 3.1% in the second quarter, HoldingsChannel reports. The institutional investor owned 13,091,481 shares of the medical equipment provider’s stock after selling 422,290 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Boston Scientific were worth $558,744,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. New Mexico Educational Retirement Board increased its position in shares of Boston Scientific by 7.3% in the second quarter. New Mexico Educational Retirement Board now owns 73,762 shares of the medical equipment provider’s stock valued at $3,148,000 after acquiring an additional 5,000 shares during the period. Royal London Asset Management Ltd. grew its stake in shares of Boston Scientific by 13.1% in the second quarter. Royal London Asset Management Ltd. now owns 753,076 shares of the medical equipment provider’s stock worth $32,141,000 after purchasing an additional 87,185 shares during the last quarter. Toth Financial Advisory Corp increased its holdings in Boston Scientific by 569.1% during the 2nd quarter. Toth Financial Advisory Corp now owns 823 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 700 shares during the period. Mufg Securities Americas Inc. increased its holdings in Boston Scientific by 9.1% during the 2nd quarter. Mufg Securities Americas Inc. now owns 44,767 shares of the medical equipment provider’s stock valued at $1,911,000 after purchasing an additional 3,731 shares during the period. Finally, Van ECK Associates Corp raised its position in Boston Scientific by 7.0% during the 2nd quarter. Van ECK Associates Corp now owns 94,958 shares of the medical equipment provider’s stock valued at $4,053,000 after purchasing an additional 6,185 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney acquired 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Habiger bought 2,100 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the purchase, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 194,522 shares of company stock valued at $9,385,210 in the last three months. Company insiders own 0.34% of the company’s stock.

Boston Scientific Trading Down 0.0%

NYSE BSX opened at $46.82 on Monday. The firm has a market capitalization of $67.85 billion, a PE ratio of 18.96, a P/E/G ratio of 1.02 and a beta of 0.56. The stock’s 50 day moving average is $46.56 and its 200 day moving average is $56.53. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the firm posted $0.75 earnings per share. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a stock repurchase plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Truist Financial cut their price objective on Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Zacks Research lowered Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Citigroup cut their price target on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Wolfe Research downgraded shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Finally, Raymond James Financial restated an “outperform” rating and issued a $57.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.